Get started
Author

Tushar Srivastava

Observed names: T Srivastava, T. Srivastava
ORCID: 0000-0002-5961-9348
Observed ORCID: 0000-0002-5961-9348
OpenAlex ID: A5088081543
Living Health Technology Assessment: Issues, Challenges and Opportunities
2023 · Praveen Thokala, Tushar Srivastava, et al. · PharmacoEconomics · 38
PDF
Estimation of Transition Probabilities for State-Transition Models: A Review of NICE Appraisals
2021 · Tushar Srivastava, Nicholas R. Latimer, et al. · PharmacoEconomics · 23
Electronic clinical decision support tool for assessing stomach symptoms in primary care (ECASS): a feasibility study
2021 · Greg Rubin, Fiona M Walter, et al. · BMJ Open · 23
PDF
Cost-Effectiveness of Lenvatinib Compared with Sorafenib for the First-Line Treatment of Advanced Hepatocellular Carcinoma in Australia
2020 · Masnoon Saiyed, Joshua Byrnes, et al. · Clinical Drug Investigation · 23
Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden
2018 · Tushar Srivastava, Vimalanand S. Prabhu, et al. · European Urology Oncology · 18
PDF
Role of Culture, Values, and Politics in the Implementation of Health Technology Assessment in India: A Commentary
2019 · Shilpi Swami, Tushar Srivastava · Value in Health · 16
PDF
Early Discharge From Intensive Care After Cardiac Surgery is Feasible With an Adequate Fast Track, Stepdown Unit: Waikato Experience
2018 · Damian Gimpel, Satya Shanbhag, et al. · Heart Lung and Circulation · 16
Cefiderocol for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model
2024 · Beth Woods, Laetitia Schmitt, et al. · Health Technology Assessment · 7
PDF
Ceftazidime with avibactam for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model
2024 · Sue Harnan, Ben Kearns, et al. · Health Technology Assessment · 6
A Systematic Review and Statistical Analysis of Factors Influencing the Cost-Effectiveness of Transcatheter Aortic Valve Implantation for Symptomatic Severe Aortic Stenosis
2023 · Laura Heathcote, Tushar Srivastava, et al. · ClinicoEconomics and Outcomes Research · 5
PDF
MSR44 Can Gen-AI Plugins Work as a Savior for MS-Excel Based Health Economic Models?
2024 · T Srivastava, S Swami · Value in Health · 4
PDF
EE504 Leveraging Large Language Models for Conceptualizing Health Economic Models: A Feasibility Study in Oncology
2024 · T Srivastava, S Swami, et al. · Value in Health · 3
MSR228 Can Gen-AI Assist in Interpreting the Health Economic Model Results as Per Target Audience?
2024 · S Swami, T Srivastava · Value in Health · 3
PDF
Improving Cycle Corrections in Discrete Time Markov Models: A Gaussian Quadrature Approach
2020 · Tushar Srivastava, Mark Strong, et al. · medRxiv · 3
PDF
PCR152 Can We Speak to GPT to Inform Patient Preference Studies?
2024 · R Sharma, S Swami, et al. · Value in Health · 2
PDF
Toxicity, Progression-Free Survival, and Quality of Life of Patients Treated with Zanubrutinib Versus Ibrutinib: A Q-TWiST Analysis from the ALPINE Study in Relapsed or Refractory Chronic Lymphocytic Leukemia
2023 · Vincent Levy, Tushar Srivastava, et al. · Blood · 2
PDF
MSR156 NICE and CDA Assessment of Artificial Intelligence-Enabled Health Technologies: Analysis and Insights
2025 · Saeed Anwar, Raju Gautam, et al. · Value in Health · 1
Zanubrutinib versus acalabrutinib indirect treatment comparison in relapsed or refractory mantle cell lymphoma
2025 · Bijal Shah, Swetha Challagulla, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 1
PDF
SA30 Are You Still Not Integrating Gen-AI Frameworks in HEOR Workflows? It's No Longer Optional!
2025 · Tushar Srivastava · Value in Health · 1
SA27 A Review of Guidelines and Checklists for the Use of Artificial Intelligence/Machine Learning (AI/ML) in Evidence Generation: Current Landscape and Recommendations
2025 · Raju Gautam, Saeed Anwar, et al. · Value in Health · 1
Toxicity, progression-free survival, and quality of life of patients treated with zanubrutinib versus ibrutinib: a Q-TWiST analysis from the ALPINE study in relapsed or refractory chronic lymphocytic leukemia
2025 · Vincent Lévy, Tushar Srivastava, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 1
PDF
MSR233 Thinking Enough? Evaluating Advanced Large Language Models' Reasoning Algorithms in HEOR
2024 · T Srivastava, S Swami · Value in Health · 1
MSR41 Human vs Machine: Gen-AI Frameworks and Recommendations in HEOR
2024 · S Swami, T Srivastava · Value in Health · 1
CO130 Q-TWiST Analysis Is Back in the Game in Oncology Clinical Trial Analysis: A Recent Trend
2023 · L. Mohseninejad, T. Srivastava, et al. · Value in Health · 1
MSR114 Current Scenario of ‘Scenario Analysis’ in Health Economic Modelling in Oncology: A Review of NICE Appraisals
2022 · T Srivastava, K Hriday · Value in Health · 1
Works count: 57
Citation count: 202
H-index: 7
I10-index: 7
Year
Topic
Type